Image Analysis Group (IAG), a company known for its expertise in clinical trial imaging and AI-driven biomarkers, has bolstered its presence in the United States by opening a new office in Cambridge, Massachusetts. This strategic move positions IAG closer to a hub of biotechnology and pharmaceutical companies, enhancing its ability to forge stronger partnerships and offer more localized support for clinical trials in the region.
The Cambridge office will play a pivotal role in IAG’s operations across various therapeutic areas, such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. It is anticipated that this new location will facilitate closer collaboration with sponsors and contract research organizations (CROs) engaged in Phase I–III clinical trials and imaging-intensive development programs. Over the next 12 to 24 months, IAG plans to generate employment opportunities in fields including clinical imaging operations, data science, regulatory support, and business development.
IAG’s expansion in the Boston life-sciences ecosystem is expected to enhance collaboration with biotechnology firms, pharmaceutical enterprises, academic institutions, and clinical research centers. The new office will provide comprehensive imaging services, including clinical trial design consultation, optimization of imaging protocols, centralized image analysis, and the delivery of regulatory-compliant data.
With its global operations spanning North America, Europe, and the Asia-Pacific region, IAG collaborates with pharmaceutical, biotechnology, and medtech companies, along with CROs, to conduct multi-center studies. The company’s international framework ensures standardized imaging protocols, centralized data harmonization, and consistent imaging analysis across the global landscape of clinical trials.
Founded in 2007 and headquartered in London, IAG operates as an imaging Clinical Research Organization (iCRO). It supports pharmaceutical, biotechnology, and medical technology companies by providing imaging-based clinical trial endpoints. IAG’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight to advance research in oncology, inflammatory disease, musculoskeletal, cardiometabolic, and rare disease indications. For further information, IAG can be reached via their website, email, or through their press contact, Marie Fussell.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.